Eli Lilly and Co (LLY)
775.84
-11.18
(-1.42%)
USD |
NYSE |
May 16, 13:56
Eli Lilly Cash from Financing (Quarterly): -311.30M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -311.30M |
| December 31, 2023 | 3.545B |
| September 30, 2023 | 572.00M |
| June 30, 2023 | -1.033B |
| March 31, 2023 | 412.30M |
| December 31, 2022 | -1.141B |
| September 30, 2022 | -1.263B |
| June 30, 2022 | -123.70M |
| March 31, 2022 | -2.878B |
| December 31, 2021 | -1.526B |
| September 30, 2021 | -463.20M |
| June 30, 2021 | -1.083B |
| March 31, 2021 | -1.058B |
| December 31, 2020 | -1.292B |
| September 30, 2020 | -279.10M |
| June 30, 2020 | -1.673B |
| March 31, 2020 | 106.70M |
| December 31, 2019 | -1.114B |
| September 30, 2019 | -1.693B |
| June 30, 2019 | -885.80M |
| March 31, 2019 | 1.368B |
| December 31, 2018 | -1.640B |
| September 30, 2018 | 432.70M |
| June 30, 2018 | -831.40M |
| March 31, 2018 | -3.866B |
| Date | Value |
|---|---|
| December 31, 2017 | -542.30M |
| September 30, 2017 | 500.70M |
| June 30, 2017 | 1.060B |
| March 31, 2017 | -875.70M |
| December 31, 2016 | 385.20M |
| September 30, 2016 | -600.10M |
| June 30, 2016 | 579.30M |
| March 31, 2016 | -924.20M |
| December 31, 2015 | -871.40M |
| September 30, 2015 | -595.20M |
| June 30, 2015 | -943.20M |
| March 31, 2015 | -701.20M |
| December 31, 2014 | 1.537B |
| September 30, 2014 | -405.90M |
| June 30, 2014 | -702.50M |
| March 31, 2014 | -595.10M |
| December 31, 2013 | -1.036B |
| September 30, 2013 | -529.00M |
| June 30, 2013 | -533.80M |
| March 31, 2013 | -1.730B |
| December 31, 2012 | -1.265B |
| September 30, 2012 | -544.70M |
| June 30, 2012 | -552.70M |
| March 31, 2012 | -2.057B |
| December 31, 2011 | -650.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.878B
Minimum
Mar 2022
3.545B
Maximum
Dec 2023
-659.16M
Average
-1.046B
Median
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | -1.708B |
| Biogen Inc | -439.60M |
| Johnson & Johnson | 546.00M |
| Vertex Pharmaceuticals Inc | -357.50M |
| Viking Therapeutics Inc | 606.04M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.166B |
| Cash from Investing (Quarterly) | -1.178B |
| Free Cash Flow | -3.896B |
| Free Cash Flow Per Share (Quarterly) | 0.0921 |
| Free Cash Flow to Equity (Quarterly) | -902.90M |
| Free Cash Flow to Firm (Quarterly) | 201.53M |
| Free Cash Flow Yield | -0.56% |